12/1
08:30 am
bdrx
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
Medium
Report
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
11/24
08:30 am
bdrx
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
Low
Report
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
11/7
01:12 am
bdrx
Biodexa Pharmaceuticals (NASDAQ:BDRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Biodexa Pharmaceuticals (NASDAQ:BDRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
11/3
08:30 am
bdrx
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
Medium
Report
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
10/27
05:31 pm
bdrx
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
Medium
Report
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
10/27
05:31 pm
bdrx
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
Medium
Report
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
10/6
08:37 am
bdrx
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 [Yahoo! Finance]
Low
Report
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 [Yahoo! Finance]
10/6
08:30 am
bdrx
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
Low
Report
Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025
9/26
05:33 pm
bdrx
Biodexa Pharmaceuticals files $100M shelf for flexible securities offerings [Seeking Alpha]
Medium
Report
Biodexa Pharmaceuticals files $100M shelf for flexible securities offerings [Seeking Alpha]
9/12
08:44 am
bdrx
Interim results for the six months ended June 30, 2025 [Yahoo! Finance]
Low
Report
Interim results for the six months ended June 30, 2025 [Yahoo! Finance]
9/12
08:30 am
bdrx
Interim results for the six months ended June 30, 2025
Low
Report
Interim results for the six months ended June 30, 2025